Retrospective Study
Copyright ©The Author(s) 2017.
World J Gastroenterol. Jan 28, 2017; 23(4): 668-675
Published online Jan 28, 2017. doi: 10.3748/wjg.v23.i4.668
Figure 1
Figure 1 Helicobacter pylori eradication rates (full analysis set) for vonoprazan, esomeprazole, rabeprazole, and lansoprazole in first-line triple therapy. The eradication rate was significantly higher in the VPZ group than that in the EPZ, RPZ, and LPZ groups (aP < 0.05); cP < 0.05 vs lansoprazole. VPZ 20: 20 mg VPZ, 200 mg CAM, and 750 mg AMPC twice a day for 1 wk. EPZ 20: 20 mg EPZ, 200 mg CAM, and 750 mg AMPC twice a day for 1 wk. RPZ 10: 10 mg RPZ, 200 mg CAM, and 750 mg AMPC twice a day for 1 wk. LPZ 30: 30 mg LPZ, 200 mg CAM, and 750 mg AMPC twice a day for 1 wk. VPZ: Vonoprazan; EPZ: Esomeprazole; CAM: Clarithromycin; AMPC: Amoxicillin; RPZ: Rabeprazole; LPZ: Lansoprazole; H. pylori: Helicobacter pylori.
Figure 2
Figure 2 Helicobacter pylori eradication rates (full analysis set) for vonoprazan, esomeprazole, rabeprazole, and lansoprazole in second-line triple therapy. The eradication rates of the four second-line therapies were not significantly different. VPZ 20: 20 mg VPZ, 250 mg MNZ, and 750 mg AMPC twice a day for 1 wk; EPZ 20: 20 mg EPZ, 250 mg MNZ, and 750 mg AMPC twice a day for 1 wk; RPZ 10: 10 mg RPZ, 250 mg MNZ, and 750 mg AMPC twice a day for 1 wk; LPZ 30: 30 mg LPZ, 250 mg MNZ, and 750 mg AMPC twice a day for 1 wk. VPZ: Vonoprazan; MNZ: Metronidazole; AMPC: Amoxicillin; EPZ: Esomeprazole; RPZ: Rabeprazole; LPZ: Lansoprazole; H. pylori: Helicobacter pylori.